



Cancer and Hematology Center

Clinical trials



As a recognized leader in clinical, translational and laboratory research, we offer clinical trials for a wide range of children's cancer and blood disorders.



See below for a list of featured trials. These are also available on our website by scanning the QR code or visiting texaschildrens.org/ClinTrials

To learn more about our international services, visit: texaschildrens.org/international

Featured clinical trials 2024

Solid Tumors

Phase 1 immunotherapy trial using **15.GPC3-CAR T cells** for children with **solid tumors, including liver, kidney and other rare cancers.**

Phase 1 study of **irinotecan liposomal** with talazoparib or temozolomide in children with recurrent **solid tumors or Ewing sarcoma (ONITT).**

Phase 1 immunotherapy trial for children with relapsed or refractory **sarcoma** using a combination of **HER2-CAR T cells** with checkpoint blockade (HEROS 3.0).



Texas Children's
Hospital

Featured clinical trials 2024 (continued)

Brain Tumors

A multi-center **HER2-CAR T-cell** immunotherapy trial for children with relapsed or refractory **ependymoma** (PBTC-059).

Evaluating anti-tumor activity of second-generation **GD2.CAR T cells** for patients with **GD2-expressing brain tumors** (GAIL-B).

Leukemias/Lymphomas

Phase 1 study of a novel **trivalent CAR-T cell therapy** for patients with refractory or recurrent **B cell acute lymphoblastic leukemia (+CD19, +CD20 and/or +CD22)** (TRICAR-ALL).

Phase 1 immunotherapy trial using next generation **CD30.CAR T cells** for refractory **lymphoma (Hodgkin or non-Hodgkin, including ALCL)** (RELY 30).

Phase 1 trial using next generation **CD5.CAR T cells** for recurrent **T-cell leukemia/lymphoma** (MAGENTA).

Phase 1 cell therapy for children with high-risk **T-cell malignancies** using **CD7- specific CAR** expressed on autologous T cells (CRIMSON).

Histiocytic Diseases

Study for patients newly diagnosed with **Langerhan's cell histiocytosis** to compare **vinblastine/prednisone** versus cytarabine (LCH-REASON).

Frontline study of **cobimetinib** in patients with recurrent or refractory **histiocytic diseases** (NACHO COBI).

Evaluation of **ELA026** monoclonal antibody for safety and efficacy as a treatment for patients with secondary **hemophagocytic lymphohistiocytosis**.

Blood, Immune and Vascular Disorders

Study to evaluate **Eltrombopag** for newly diagnosed **immune thrombocytopenia (ITP)** in children.

Phase 2 trial for **MAS825** in patients with monogenic **IL-18 driven autoinflammatory diseases**, including **NLR4-GOF, XIAP deficiency or CDC42 mutations** (MAStEr-1).

A Phase 2 study for **alpelisib (BYL719)** in pediatric and adult patients with **PIK3CA-related overgrowth spectrum** (EPIK-P2).

